ArticleOncotarget2015

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.

Dany A Curi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.